Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hospital of the University of Pennsylvania, 4 Maloney, 3400 Spruce Street, Philadelphia, PA, 19104, USA.
Ann Surg Oncol. 2022 Aug;29(8):5207-5216. doi: 10.1245/s10434-022-11478-4. Epub 2022 Mar 17.
The prognostic impact of tumor-infiltrating lymphocytes (TILs) on outcomes and treatment efficacy for patients with melanoma in the contemporary era remains poorly characterized.
Consecutive patients who underwent wide excision and sentinel lymph node biopsy for cutaneous melanoma 1 mm thick or thicker at a single institution were identified (2006-2019). The patients were stratified based on primary tumor TIL status as brisk (bTILs), non-brisk (nbTILs), or absent (aTILs). Associations between patient factors and outcomes were analyzed using multivariable analysis.
Of the 1017 patients evaluated, 846 (83.2 %) had primary TILs [nbTILs (n = 759, 89.7 %) and bTILs (n = 87, 10.3 %)]. In the multivariable analysis, the patients with any type of TILs had higher rates of regression [odds ratio (OR), 1.86; p = 0.016], lower rates of acral lentiginous histology (OR, 0.22; p < 0.001), and lower rates of SLN positivity (OR, 0.64; p = 0.042) than those without TILs. The multivariable analysis found no association between disease-specific survival and bTILs [hazard ratio (HR), 1.04; p = 0.927] or nbTILs (HR, 0.89; p = 0.683). An association was found between bTILs and recurrence-free survival (RFS) advantage [bTILs (HR 0.46; p = 0.047), nbTILs (HR 0.71; p = 0.088)], with 5-year RFS rates of 84 % for bTILs, 71.8 % for nbTILs, and 68.4 % for aTILs (p = 0.044). For the 114 immune checkpoint blockade (ICB)-naïve patients who experienced a recurrence treated with ICB therapy, no association was observed between progression-free survival and bTILs (HR, 0.64; p = 0.482) or nbTILs (HR, 0.58; p = 0.176).
The prognostic significance of primary TILs in the contemporary melanoma era appears complex. Further studies characterizing the phenotype of TILs and their association with regional metastasis and responsiveness to ICB therapy are warranted.
在当代,肿瘤浸润淋巴细胞(TILs)对黑色素瘤患者结局和治疗效果的预后影响仍未得到充分描述。
本研究连续纳入了在单家机构接受手术切除和前哨淋巴结活检的 1 毫米或更厚的皮肤黑色素瘤患者(2006 年至 2019 年)。根据原发肿瘤 TIL 状态将患者分为以下几类:活跃型(bTILs)、非活跃型(nbTILs)或不存在(aTILs)。采用多变量分析方法分析患者因素与结局之间的关系。
在评估的 1017 例患者中,846 例(83.2%)有原发性 TILs[nbTILs(n=759,89.7%)和 bTILs(n=87,10.3%)]。多变量分析发现,有任何类型 TILs 的患者更有可能出现消退(比值比 [OR],1.86;p=0.016),发生肢端黑色素瘤的组织学类型(OR,0.22;p<0.001)和前哨淋巴结阳性(OR,0.64;p=0.042)的几率较低。多变量分析发现 bTILs 与疾病特异性生存之间无相关性[风险比(HR),1.04;p=0.927]或 nbTILs(HR,0.89;p=0.683)。bTILs 与无复发生存率(RFS)优势相关(bTILs[HR 0.46;p=0.047],nbTILs[HR 0.71;p=0.088]),bTILs 的 5 年 RFS 率为 84%,nbTILs 为 71.8%,aTILs 为 68.4%(p=0.044)。在 114 例接受免疫检查点阻断(ICB)治疗的复发 ICB 治疗的初治患者中,无复发生存率与 bTILs(HR,0.64;p=0.482)或 nbTILs(HR,0.58;p=0.176)之间无相关性。
在当代黑色素瘤时代,原发性 TILs 的预后意义似乎较为复杂。进一步研究 TILs 的表型及其与区域转移和对 ICB 治疗反应的相关性是必要的。